DK2245037T3 - Nye forbindelser og fremgangsmåder for terapi - Google Patents

Nye forbindelser og fremgangsmåder for terapi

Info

Publication number
DK2245037T3
DK2245037T3 DK09712645.2T DK09712645T DK2245037T3 DK 2245037 T3 DK2245037 T3 DK 2245037T3 DK 09712645 T DK09712645 T DK 09712645T DK 2245037 T3 DK2245037 T3 DK 2245037T3
Authority
DK
Denmark
Prior art keywords
therapy
methods
new connections
connections
new
Prior art date
Application number
DK09712645.2T
Other languages
English (en)
Inventor
William J Watkins
Adrian S Ray
Daniel Tumas
Gabriel Birkus
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK2245037T3 publication Critical patent/DK2245037T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plasma & Fusion (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09712645.2T 2008-02-20 2009-02-19 Nye forbindelser og fremgangsmåder for terapi DK2245037T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3014808P 2008-02-20 2008-02-20
PCT/US2009/034471 WO2009105513A2 (en) 2008-02-20 2009-02-19 Novel compounds and methods for therapy

Publications (1)

Publication Number Publication Date
DK2245037T3 true DK2245037T3 (da) 2014-09-29

Family

ID=40532651

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09712645.2T DK2245037T3 (da) 2008-02-20 2009-02-19 Nye forbindelser og fremgangsmåder for terapi
DK11151008.7T DK2308885T3 (da) 2008-02-20 2009-02-19 Nye forbindelser og fremgangsmåder for terapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11151008.7T DK2308885T3 (da) 2008-02-20 2009-02-19 Nye forbindelser og fremgangsmåder for terapi

Country Status (18)

Country Link
US (1) US8163718B2 (da)
EP (2) EP2245037B1 (da)
JP (2) JP5588356B2 (da)
KR (2) KR101612138B1 (da)
CN (2) CN102015739B (da)
AR (1) AR071159A1 (da)
AU (3) AU2009215547B2 (da)
CA (1) CA2715885C (da)
CY (2) CY1115571T1 (da)
DK (2) DK2245037T3 (da)
ES (2) ES2516715T3 (da)
HR (2) HRP20140895T1 (da)
NZ (1) NZ587464A (da)
PL (2) PL2308885T3 (da)
PT (2) PT2245037E (da)
SI (2) SI2308885T1 (da)
TW (1) TWI444384B (da)
WO (1) WO2009105513A2 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2684957A2 (en) 2009-01-08 2014-01-15 International Institute of Cancer Immunology, Inc. Double-stranded siRNA targeting cancer antigen eEF2
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CN102093422B (zh) * 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
SG11201503893RA (en) 2012-11-19 2015-06-29 Agency Science Tech & Res Method of treating cancer
EA201590396A1 (ru) * 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
SMT201800538T1 (it) 2013-03-15 2019-01-11 Univ California Diesteri di fosfonato nucleosidico aciclico
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
HRP20220651T1 (hr) 2014-09-15 2022-08-19 The Regents Of The University Of California Nukleotidni analozi
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TWI639598B (zh) * 2015-08-10 2018-11-01 美商默沙東藥廠 抗病毒β－胺基酸酯磷酸二醯胺化合物
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EA201892460A1 (ru) * 2016-05-04 2019-09-30 Би.Си.Ай. ФАРМА Производные аденина как ингибиторы протеинкиназ
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
MA47131A (fr) 2016-12-22 2021-05-12 Idenix Pharmaceuticals Llc Composés benzyl-amide phosphodiamide antiviraux
KR20190100250A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 테노포비르의 항바이러스 지방족 에스테르 전구약물
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
CN112778363B (zh) * 2019-11-05 2024-03-15 华创合成制药股份有限公司 一种硝基咪唑类唑衍生物及其制备方法和用途
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US3665838A (en) * 1970-01-29 1972-05-30 Wilson Lighting Ltd Air chamber assembly
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
EP0159604B1 (en) 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US5141752A (en) 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
AU613592B2 (en) 1986-11-18 1991-08-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosophonomethoxy-alkyene purine and pyrimide derivatives
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
GB8802142D0 (en) * 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
CA2479846C (en) 1989-05-15 2007-07-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
PT95516A (pt) 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
WO1992001698A1 (en) 1990-07-19 1992-02-06 Beecham Group Plc Antiviral phosphono-alken derivatives of purines
EP0468119A1 (en) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
JP3497505B2 (ja) 1991-10-11 2004-02-16 インスティテュート オブ オルガニック ケミストリー アンド バイオケミストリー オブ ザ アカデミー オブ サイエンシズ オブ ザ チェコ パブリック 抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
ATE199906T1 (de) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
IL120202A (en) * 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
DE60118521T2 (de) * 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
FR2862306B1 (fr) * 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
HRP20100626T1 (hr) * 2003-12-30 2011-03-31 Gilead Sciences Fosfonati, monofosfonamidati, bisfosfonamidati za liječenje virusnih bolesti
ATE542095T1 (de) * 2004-07-23 2012-02-15 Bayer Technology Services Gmbh Verfahren zum sterilen gefrieren, trocknen, lagern, analysieren und füllen (sfd-saf- verfahren) (verfahren zur gefriertrocknung von granulat für parenterale biopharmazeutika)
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007002808A1 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
KR101424832B1 (ko) 2006-05-16 2014-08-06 길리애드 사이언시즈, 인코포레이티드 악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
US9521854B2 (en) * 2006-05-31 2016-12-20 Air Liquide Industrial U.S. Lp Method and device for creating frozen pellets of a foodstuff
PT2038290E (pt) * 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
CN101066981B (zh) * 2007-05-25 2011-10-05 中国科学院上海药物研究所 非环核苷膦酸酯类化合物及其组合物、制备方法和用途

Also Published As

Publication number Publication date
PT2245037E (pt) 2014-10-24
PL2308885T3 (pl) 2015-04-30
AU2009215547A1 (en) 2009-08-27
SI2245037T1 (sl) 2014-12-31
CY1116015T1 (el) 2017-01-25
CN102015739A (zh) 2011-04-13
CA2715885A1 (en) 2009-08-27
AU2014203786B2 (en) 2016-11-17
TW200948823A (en) 2009-12-01
PT2308885E (pt) 2015-02-10
CY1115571T1 (el) 2017-01-04
EP2308885A2 (en) 2011-04-13
HRP20150005T1 (hr) 2015-04-24
HK1156631A1 (en) 2012-06-15
HK1150313A1 (en) 2011-11-25
DK2308885T3 (da) 2015-02-23
US8163718B2 (en) 2012-04-24
CA2715885C (en) 2016-06-28
AR071159A1 (es) 2010-06-02
TWI444384B (zh) 2014-07-11
CN105753905A (zh) 2016-07-13
WO2009105513A2 (en) 2009-08-27
ES2529209T3 (es) 2015-02-18
KR101728647B1 (ko) 2017-04-19
KR20100127242A (ko) 2010-12-03
EP2245037B1 (en) 2014-06-18
JP2014088416A (ja) 2014-05-15
EP2308885A3 (en) 2011-05-11
KR101612138B1 (ko) 2016-04-12
ES2516715T3 (es) 2014-10-31
AU2014203786A1 (en) 2014-07-31
PL2245037T3 (pl) 2015-01-30
US20090232768A1 (en) 2009-09-17
JP5588356B2 (ja) 2014-09-10
AU2009215547B2 (en) 2014-04-10
PL2245037T4 (pl) 2015-06-30
SI2308885T1 (sl) 2015-03-31
KR20160041061A (ko) 2016-04-15
CN102015739B (zh) 2016-03-09
EP2308885B1 (en) 2014-11-19
HRP20140895T1 (hr) 2014-12-19
NZ587464A (en) 2012-07-27
JP2011514336A (ja) 2011-05-06
WO2009105513A3 (en) 2009-11-12
WO2009105513A8 (en) 2009-11-12
AU2016250468A1 (en) 2016-11-17
EP2245037A2 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
DK2308885T3 (da) Nye forbindelser og fremgangsmåder for terapi
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
PL2640375T3 (pl) Sposób leczenia nefropatii pokontrastowej
DK3622815T3 (da) Gnavermodeller og terapeutiske molekyler
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2563531T3 (da) Fremgangsmåde og indretning til fordøjelse af væv
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BRPI1013655A8 (pt) dispositivo e método cirúrgico
DK2428450T3 (da) Doseringsmetode og doseringsindretning
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
PL3056224T3 (pl) Sposób sterylizacji
DK2482871T3 (da) Anti-bolus-kontrol metode og tilsvarende enhed
NO20085219L (no) Koplingsarrangement og fremgangsmate for forspent sammenkopling
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
IL218738A (en) Inspection method and apparatus
BR112012015031A2 (pt) aparelho e método
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2295646T3 (da) Boreindretning og borefremgangsmåde
BRPI1007909A2 (pt) método e dispositivo médico
DK2407629T3 (da) Boreindretning og borefremgangsmåde